Physician profile
Pomilla C Kumar
NPI 1568431880
$7,930.86
in general payments reported to CMS, 2019-2025
56 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $1,289 · 2021: $1,653 · 2022: $1,228 · 2023: $1,217 · 2024: $1,108 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $877.16 | 2019-2024 | Breztri, Airsupra, Flumist Quadrivalent |
| Novo Nordisk INC | $657.74 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $585.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $572.46 | 2022-2025 | Rexulti |
| Pfizer INC. | $567.04 | 2019-2025 | |
| Lilly USA, LLC | $365.91 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $295.71 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $295.35 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $278.99 | 2019-2024 | |
| Glaxosmithkline, LLC. | $246.26 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $238.99 | 2019-2024 | Xarelto |
| Amgen INC. | $224.65 | 2019-2022 | |
| Allergan, INC. | $195.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.02 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $178.42 | 2019-2023 | Eliquis |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pomilla Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.